Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Serious allergic reactions to COVID-19 vaccines are very rare, with most vaccines showing low incidence rates. This indicates that coronavirus disease 2019 (COVID-19) vaccines are generally safe for public use.
Area Of Science
- Immunology
- Vaccinology
- Public Health
Background
- The COVID-19 pandemic necessitated rapid vaccine development and mass vaccination campaigns.
- Concerns regarding post-vaccination allergic reactions have been raised, necessitating comprehensive safety data.
- Previous studies on COVID-19 vaccine allergies were often limited in scope or focused narrowly on anaphylaxis.
Purpose Of The Study
- To analyze the incidence of serious allergic reactions following COVID-19 vaccination using the EudraVigilance database.
- To assess the allergic potential of various COVID-19 vaccines irrespective of reaction type or mechanism.
- To provide a broader understanding of vaccine safety concerning allergic responses.
Main Methods
- Extracted COVID-19 vaccine administration data from Vaccine Tracker up to October 5, 2023, for the European Economic Area.
- Queried the EudraVigilance database for serious allergic reactions associated with COVID-19 vaccines within the same timeframe.
- Utilized a comprehensive list of 147 allergic symptoms and diseases for data analysis.
Main Results
- Incidence rates per 100,000 doses varied: Comirnaty (1.53), Spikevax (2.16), Vaxzevria (88.6), Janssen (2.11), Novavax (7.9), VidPrevtyn Beta (13.3), and Valneva (3.1).
- The most frequent serious reactions reported were edema (0.46/100,000) and anaphylaxis (0.40/100,000).
- Delayed hypersensitivity reactions accounted for only 6% of the reported serious allergic events.
Conclusions
- The overall incidence of serious allergic reactions to COVID-19 vaccines is very low, suggesting a favorable safety profile.
- COVID-19 vaccines demonstrate a good safety record for the general population.
- Comirnaty exhibited the lowest frequency of allergic reactions, while Vaxzevria showed the highest among the studied vaccines.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Overview
We speak of an allergy when the immune system triggers a response against a benign foreign structure, like food, pollen or pet dander. These elicitors are called allergens. If the immune system of a hypersensitive individual was primed against a specific allergen, it will trigger allergic symptoms during every subsequent encounter of the allergen. Symptoms can be mild, such as hay fever, to severe, such as potentially fatal anaphylactic shock.
Sensitization Is the First Step of an...
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Overview
The ability of a single antibody to recognize multiple structurally similar epitopes is an important immune defense strategy that enables the host to efficiently defend against many potentially threatening pathogens. However, cross-reactivity also elicits allergy symptoms against related allergens. It is increasingly important to understand the principles of cross-reactivity, as antibodies are actively being developed as therapeutic modalities for diverse diseases, including cancer.